Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
Safety Study of Dexmedetomidine in Elderly Under General Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Zhenjiang First People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05567523
- Locations
- 🇨🇳
Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China
The Effect of MDZ on Movement During UIA Clipping
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT05553678
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT05550636
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 37
- Registration Number
- NCT05541471
- Locations
- 🇺🇸
Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05537090
- Locations
- 🇭🇺
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05530278
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 248824, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 248823, Miami, Florida, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 248853, Las Vegas, Nevada, United States
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT05526911
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT05518799
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT05518734
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
Efficacy of Virtual Reality Distraction Technique for Anxiety and Pain Control in Orthopedic Forearm Surgeries Performed Under Supraclavicular Brachial Plexus Block
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 30
- Registration Number
- NCT05512728
- Locations
- 🇪🇬
Kasr Alainy, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.